Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000808

Fenilbutirato de sodio

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

4-Fenilbutirato de sodio, 4-PBA, 4-fenilbutirato, Buphenyl, TriButirato, Ácido 4-fenilbutírico

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H11NaO2
Número de CAS:
1716-12-7
Peso molecular:
186.18
Número MDL:
MFCD00800247
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831161
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

sodium phenylbutyrate

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1

Clave InChI

VPZRWNZGLKXFOE-UHFFFAOYSA-M

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

El fenilbutirato de sodio es un inhibidor de las histona deacetilasas.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000809

Sodium phenylbutyrate impurity C, European Pharmacopoeia (EP) Reference Standard

1614512

Fenilbutirato de sodio, United States Pharmacopeia (USP) Reference Standard

1614556

Phenylbutyrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1614523

Phenylbutyrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1614534

Phenylbutyrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR3080

Phenylbutyrate Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3081

Phenylbutyrate Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3082

Phenylbutyrate Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3237

Fenilbutirato de sodio, pharmaceutical secondary standard, certified reference material

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
A F List
Leukemia research, 22 Suppl 1, S7-11 (1998-09-12)
Viola Pomozi et al.
The Journal of investigative dermatology, 134(4), 946-953 (2013-12-20)
Mutations in the ABCC6 gene cause soft-tissue calcification in pseudoxanthoma elasticum (PXE) and, in some patients, generalized arterial calcification of infancy (GACI). PXE is characterized by late onset and progressive mineralization of elastic fibers in dermal, ocular, and cardiovascular tissues.
Sotaro Naoi et al.
The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)
To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile
Elisabeth Kemter et al.
The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)
Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive
Wei Zeng et al.
Life sciences, 103(1), 15-24 (2014-03-22)
Endoplasmic reticulum (ER) stress is involved in the pathogenesis of atherosclerosis (AS). Endothelial cell (EC) dysfunction and monocyte migration to the subendothelium are considered to be essential manifestations of AS. We conducted this study to determine whether ER stress was
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico